Maureen A Chung1, Margaret M Steinhoff, Blake Cady. 1. The Breast Health Center, Women and Infants Hospital, and Department of Surgery, Brown University, Providence, RI, USA. mchung@wihri.org
Abstract
BACKGROUND: The purpose of this study was to determine the axillary recurrence rate in breast cancer patients with a negative sentinel lymph node who did not have an axillary node dissection. METHODS: Sentinel lymphadenectomy for breast cancer patients, without axillary node dissection if the node was negative, was introduced in 1998 at our institution. This study includes those women with a negative sentinel lymph node. Adjuvant chemotherapy was administered based on primary tumor characteristics. If breast radiotherapy was used, no attempt was made to include the axilla. RESULTS: From January 1998 to December 2001, 206 patients (208 breast cancers) had a negative sentinel lymph node. The median age at diagnosis was 56 years and median tumor size was 1.2 cm. With a median follow-up of 26 months, there have been 3 axillary recurrences with a clinical sentinel lymph node false negative rate of 1.4%. CONCLUSIONS: In this study, the clinical false negative rate of a sentinel lymph node biopsy is 1.4%. Our study provides further evidence supporting the use of sentinel lymphadenectomy in women with breast cancer.
BACKGROUND: The purpose of this study was to determine the axillary recurrence rate in breast cancerpatients with a negative sentinel lymph node who did not have an axillary node dissection. METHODS: Sentinel lymphadenectomy for breast cancerpatients, without axillary node dissection if the node was negative, was introduced in 1998 at our institution. This study includes those women with a negative sentinel lymph node. Adjuvant chemotherapy was administered based on primary tumor characteristics. If breast radiotherapy was used, no attempt was made to include the axilla. RESULTS: From January 1998 to December 2001, 206 patients (208 breast cancers) had a negative sentinel lymph node. The median age at diagnosis was 56 years and median tumor size was 1.2 cm. With a median follow-up of 26 months, there have been 3 axillary recurrences with a clinical sentinel lymph node false negative rate of 1.4%. CONCLUSIONS: In this study, the clinical false negative rate of a sentinel lymph node biopsy is 1.4%. Our study provides further evidence supporting the use of sentinel lymphadenectomy in women with breast cancer.
Authors: John T Carlo; Michael D Grant; Sally M Knox; Ronald C Jones; Cody S Hamilton; Sheryl A Livingston; Joseph A Kuhn Journal: Proc (Bayl Univ Med Cent) Date: 2005-04
Authors: A Sanjuàn; S Vidal-Sicart; G Zanón; J Pahisa; M Velasco; P L Fernández; G Santamaría; B Farrús; M Muñoz; J Albanell; F Pons; J A Vanrell Journal: Eur J Nucl Med Mol Imaging Date: 2005-03-25 Impact factor: 9.236
Authors: Igor Langer; Walter Richard Marti; Ulrich Guller; Holger Moch; Felix Harder; Daniel Oertli; Markus Zuber Journal: Ann Surg Date: 2005-01 Impact factor: 12.969
Authors: Arpana M Naik; Jane Fey; Mary Gemignani; Alexandra Heerdt; Leslie Montgomery; Jeanne Petrek; Elisa Port; Virgilio Sacchini; Lisa Sclafani; Kimberly VanZee; Raquel Wagman; Patrick I Borgen; Hiram S Cody Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Jacqueline S Jeruss; Lisa A Newman; Gregory D Ayers; Massimo Cristofanilli; Kristine R Broglio; Funda Meric-Bernstam; Min Yi; Jennifer F Waljee; Merrick I Ross; Kelly K Hunt Journal: Cancer Date: 2008-06-15 Impact factor: 6.860